Contraceptive® SFDA Safety Communication about Using Yasmin
2011-10-31
SFDA, represented by its Drug Sector, warned about the risk of developing Venous thromboembolism (VTE) when using contraceptives containing drospirenone, e.g.Yasmin® , the sole contraceptive registered in the Kingdom that contains this substance. The warning included the increasing risk when using this product by patients with risk factors or VTE history.